GenEdit, Inc.
June 16, 2025
Company Presentation
Platform for Therapeutics
At GenEdit, our mission is to develop innovative genetic medicines with targeted in vivo delivery. Our NanoGalaxy® platform of non-viral, non-lipid hydrophilic nanoparticles (HNPs) offer a combination of advantages over other delivery methods, including tissue selectivity, payload flexibility, low immunogenicity, ability to re-dose, and ease of manufacturing. We are leveraging our platform to develop therapeutics for internal and partnered programs - including immunology, immuno-oncology, and neurology.
Company HQ City:
Brisbane
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
Lead product has not been disclosed
CEO
Kunwoo Lee
Year Founded
2016
Development Phase of Lead Product
Discovery
What is your next catalyst (value inflection) update?
End of 2025 and early 2026
Website
https://genedit.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}